Summer 2023 Symposium

Rare Tumors: Ideas for Implementation of Novel Concepts

PROGRAM BOOK

THURSDAY, JULY 20, 2023
8 AM - 12 NOON - EST
PHILADELPHIA MARRIOTT HOTEL, PHILA, PA
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formerly known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*

<table>
<thead>
<tr>
<th>NAME</th>
<th>Individual's Role(s) in Activity</th>
<th>Nothing To Disclose</th>
<th>DISCLOSURE &lt;company &amp; role&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Planning Disclosures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jubilee Brown, MD</td>
<td>Program Chair</td>
<td>Clovis Oncology; EISAI INC.; GSK; Olympus; Tesaro, Inc: Consultant Genentech:Other</td>
<td></td>
</tr>
<tr>
<td>Allan Covens, MD</td>
<td>Program Chair</td>
<td>GSK; Merck: Grant / Contract</td>
<td></td>
</tr>
<tr>
<td><strong>Speaker Disclosures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rebecca Arend, MD</td>
<td>Speaker</td>
<td>AstraZeneca; Clovis; GSK; Leap Therapeutics; Merck; Seagen; Sutro Biopharma; VBL: Other Caris Life Sciences: Consultant</td>
<td></td>
</tr>
<tr>
<td>Jubilee Brown, MD</td>
<td>Speaker/Moderator</td>
<td>Clovis Oncology; EISAI INC.; GSK; Olympus; Tesaro, Inc: Consultant Genentech:Other</td>
<td></td>
</tr>
<tr>
<td>Junzo Chino, MD</td>
<td>Speaker</td>
<td>American Brachytherapy Society; GOG Foundation: Other Duke University Medical Center: Employment KM Pharmaceutical Consulting LLC: Data And Safety Monitoring Stryker Corporation: Consultant</td>
<td></td>
</tr>
<tr>
<td>Allan Covens, MD</td>
<td>Speaker/Moderator</td>
<td>GSK; Merck: Grant / Contract</td>
<td></td>
</tr>
<tr>
<td>Danielle Enserro, PhD</td>
<td>Speaker</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Britt Erickson, MD</td>
<td>Speaker</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Amanda Fader, MD</td>
<td>Speaker/Moderator</td>
<td>Verastem, Inc: Other</td>
<td></td>
</tr>
<tr>
<td>Lillian Gien, MD</td>
<td>Speaker</td>
<td>Corcept Therapeutics; GlaxoSmithKline; Jazz Pharmaceuticals Inc.; Merck: Other Merck: Consultant</td>
<td></td>
</tr>
<tr>
<td>Rachel Grisham, MD</td>
<td>Speaker</td>
<td>AbbVie; AstraZeneca; Corpect Therapeutics; GlaxoSmithKline; Natera; Springworks; Verastem, Inc: Consultant</td>
<td></td>
</tr>
<tr>
<td>R. Tyler Hillman, MD</td>
<td>Speaker</td>
<td>Dainippon Sumitomo Pharma: Grant / Contract</td>
<td></td>
</tr>
<tr>
<td>Michael Kelly, MD</td>
<td>Speaker</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Disclosures</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Elise Kohn, MD</td>
<td>Speaker</td>
<td>X Puma Biotechnology: Grant / Contract</td>
<td></td>
</tr>
<tr>
<td>Haider Mahdi, MD</td>
<td>Speaker/Moderator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alexandra Thomas, MD</td>
<td>Speaker</td>
<td>X Eli Lilly and Company; Genentech: Consultant BeyondSpring: Data And Safety Monitoring SANOFI PASTEUR INC.: Grant / Contract Bristol-Myers Squibb; Doximity; Gilead Sciences; Johnson &amp; Johnson Health Care Systems Inc.; Pfizer: Stock Copyright: Author for Up-to-Date</td>
<td></td>
</tr>
<tr>
<td>Danielle Vicus, MD</td>
<td>Speaker</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Michelle N Small, MPH</td>
<td>Staff</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Jill Reese</td>
<td>Staff</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
Accreditation Statement
The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The GOG Foundation Inc. Continuing Education (CME) Program Mission Statement
The purpose of The GOG Foundation, Inc. CE program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

Disclosure Declaration
In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.

How do I collect CME Certificates?
Symposium Evaluation links will be emailed to all registered attendees.

- Complete the Evaluation questions.
- Click Submit, your certificate will automatically be emailed to you.


Questions?

CMEs: If you have issues accessing your certificate or questions about CME’s please contact: cmeinfo@gog.org

For questions or comments about this CME activity, please contact:
Michelle N. Small, MHA
Dir, Education Programs/CME Compliance at smallm@nrgoncology.org
Summer 2023 Symposium Agenda

Rare Tumors: Ideas for Implementation of Novel Concepts
Thursday, July 20, 2023 – 8 am to 12 pm – (ET)
NRG Oncology Summer 2023 Meeting – Philadelphia Marriott – Philadelphia, PA

Program Chairs: Jubilee Brown, MD and Allan Covens, MD

PROGRAM DESCRIPTION:
The Summer 2023 Hybrid Educational Symposium is titled “Rare Tumors: Ideas for Implementation of Novel Concepts” with noted oncologists and scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: gynecologic oncologists, medical oncologists, radiation oncologists, pathologists, patient advocates and others engaged in oncology research and/or clinical practice; oncology nurses, nurse-practitioners, and other interested allied health professionals.

The speakers will focus their presentations on the design, implementation strategies, and progress in clinical trials involving rare tumors. The information presented will span novel clinical trial design with incorporation of novel statistical design and molecular profiling. Experts will share insights on NCI funding and coordination of work with other disease sites. Attendees will learn from faculty with experience in rare gynecologic and breast cancers, incorporating radiation and surgical components, with specific emphasis on trials that have had successful outcomes.

LEARNING OBJECTIVES:
Following this activity, participants will be better able to:

1. Design clinical trials
2. Synthesize components of published clinical trials
3. Implement new strategies in patient care informed by outcomes of clinical trials in rare tumors

Presentation Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic/Title</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Breakfast Buffet</td>
<td></td>
</tr>
<tr>
<td>8:00 am</td>
<td>Welcome/Opening Remarks</td>
<td>Allan Covens, MD</td>
</tr>
<tr>
<td>8:05 am</td>
<td>Session 1 – Rare Tumor Trials: Progress and Pitfalls</td>
<td>Moderators: Jubilee Brown, MD and Amanda Fader, MD</td>
</tr>
<tr>
<td>8:05 – 8:15</td>
<td>Lessons Learned from NRG trials in Rare Gynecologic Cancers</td>
<td>Jubilee Brown, MD</td>
</tr>
<tr>
<td>8:15 – 8:30</td>
<td>Novel Trial Design and Statistics for Rare Tumor Trials</td>
<td>Danielle Enserro, PhD</td>
</tr>
<tr>
<td>8:30 – 8:45</td>
<td>NCI: Priorities and Funding for Rare Tumor Trials</td>
<td>Elise Kohn, MD</td>
</tr>
<tr>
<td>8:45 – 8:50</td>
<td>Updates in Gynecologic Rare Tumor Trials</td>
<td>Allan Covens, MD</td>
</tr>
<tr>
<td>8:50 – 9:20</td>
<td>Low Grade Serous Ovarian Cancer &amp; Should Rare Tumor Concepts be Evaluated Differently?</td>
<td>Rachel Grisham, MD</td>
</tr>
<tr>
<td>9:20 - 9:35</td>
<td>Stromal Tumors of the Ovary</td>
<td>R. Tyler Hillman, MD</td>
</tr>
<tr>
<td>9:35 – 9:45</td>
<td>Questions and discussion</td>
<td></td>
</tr>
<tr>
<td>9:45 – 10:00</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Session 2 – Rare Tumor Trial Design – Past the Surface</td>
<td>Moderators: Allan Covens, MD and Haider Mahdi, MD</td>
</tr>
<tr>
<td>10:00 – 10:15</td>
<td>Clear Cell Carcinoma</td>
<td>Lilian Gien, MD</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Presenter</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td>Update in Breast Cancer Rare Tumor Trials</td>
<td>Alexandra Thomas, MD</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>How does Molecular Profiling inform Rare Tumor Study?</td>
<td>Rebecca Arend, MD</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Role of Radiation and Surgery in Rare Tumor Trials - Surgery</td>
<td>Michael Kelly, MD</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>Role of Radiation and Surgery in Rare Tumor Trials - Radiation</td>
<td>Junzo Chino, MD</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Developing a Program of Study: Her2+ Tumors</td>
<td>Britt Erickson, MD</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>Developing Clinical Trials in previously Non-NRG Diseases and across Multi-tumor Sites</td>
<td>Danielle Vicus, MD</td>
</tr>
<tr>
<td>11:45 – 12:00 pm</td>
<td>Questions and discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Continuing Education**

**Accreditation Statement**

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

**AMA PRA Category 1 Credits™**

The GOG Foundation, Inc. designates this live internet activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Evaluation**

Participants who complete the educational activity, evaluation and attendance verification will receive a certificate of credit.

**Disclosure Declaration**

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests).*

All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. All relevant financial relationships listed for these individuals have been mitigated to ensure a bias-free presentation. Please see the faculty disclosure list for detailed information.
### Allan Covens, MD (Symposium Chair)
Professor and Chair  
Gynecologic Oncology, University of Toronto, Sunnybrook Health Sciences Center

Dr. Covens is the Professor and Chair of the division of Gynecologic Oncology at the University of Toronto, and Sunnybrook Health Sciences Center.

Dr. Covens obtained his medical degree with honors from the University of Toronto in 1983. He attended the University of Western Ontario for residency in Obstetrics and Gynecology, and the University of Toronto/McMaster University for a fellowship in Gynecologic Oncology, which was completed in 1990.

He is the author of approx. 200 peer reviewed publications, and the recipient of more than 32 scholarships and awards. He has been successful in obtaining over 33 peer-reviewed grants. He has presented over 200 abstracts at scientific meetings, and given over 200 invited lectures around the world. He has served as a visiting professor over 30 times around the world at various academic universities. He has performed live surgery on 6 continents around the world, and is on faculty at Moi University in Eldoret, Kenya. He has participated in 16 textbooks in Gynecologic Oncology, and has edited a DVD/book on laparoscopy in Gynecologic Oncology.

Dr. Covens chairs the Rare Tumour Cmte and Canadian Cmte, and is a member of the Gyn, Cervix and Gestational Trophoblastic cmtes of NRG. He also chairs the examination cmte of the global curriculum, and is a past vice president of the IGCS. He is a member of MAGIC a multidisciplinary multicooperative group team developing protocols in Malignant Germ Cell Tumours, and previous co-chair of the cervical cancer task force for the NCI (US).


His main interests and expertise include clinical trials, germ cell tumours, Gestational Trophoblastic Disease, Cervical Cancer (innovative surgical approaches, sentinel lymph nodes, and fertility sparing approaches), and Radical and Reconstructive Surgical Techniques in Gynecologic Oncology.

### Jubilee Brown, MD (Symposium Chair)
Professor and Division Director of Gynecologic Oncology  
Levine Cancer Institute at Atrium Health

Dr. Brown is Professor and Division Director of Gynecologic Oncology at Levine Cancer Institute at Atrium Health Wake Forest University in Charlotte, NC, and is a member of the Atrium Health Wake Forest University Comprehensive Cancer Center. She completed her fellowship in gynecologic oncology at the University of Texas MD Anderson Cancer Center and then spent 14 years on faculty at MD Anderson, reaching the rank of Full Professor with Tenure. Dr. Brown was the President Elect of the MD Anderson Faculty Senate prior to her move to Levine Cancer Institute. She is the past president of the AAGL and is currently a
member of the Board of Directors of the Society of Gynecologic Oncology. She is the Co-Chair of the Rare Tumor Committee of NRG Oncology. Dr. Brown has a research focus in rare tumors and minimally invasive surgery, and has served as the Principal Investigator on multiple funded collaborative group and investigator initiated trials. She has authored over 120 publications, 23 book chapters, and is an editor of the Textbook of Uncommon Cancers. She now leads a division of 6 gynecologic oncologists at the Levine Cancer Institute and initiated the first ACGME accredited gynecologic oncology fellowship program in the area. Dr. Brown has been involved in international work in oncology, teaching on 5 continents and mentoring visiting professors worldwide. She trained the first Global Scholar from Eurasia through the International Gynecologic Cancer Society (IGCS) and has worked with the American Eurasian Cancer Alliance since 2017 to provide educational support for regional conferences and tumor boards with Kazakhstan and surrounding countries.

Rebecca C. Arend, MD, MSPH
Associate Professor, University of Alabama at Birmingham
Division of Gynecologic Oncology
O’Neal Comprehensive Cancer Center

Dr. Arend is Associate Professor of Gynecologic Oncology at the University of Alabama at Birmingham (UAB) and an Associate Scientist at the UAB O’Neal Comprehensive Cancer Center Experimental Therapeutics Program. She completed her residency at Columbia Presbyterian in New York, NY and completed her fellowship at The University of Alabama at Birmingham. While a fellow at UAB, her review of the Wnt pathway in ovarian cancer became one of the 5 most cited papers in Gynecologic Oncology. After completing her fellowship, Dr. Arend continued her work in the Wnt pathway as a Principal Investigator in her lab within the O’Neal Comprehensive Cancer Center. Her current basic science pursuits include understanding the role of anti-tumor immunity in ovarian cancer through Wnt modulation, metabolism, and epigenetics.

Dr. Arend’s clinical interests include translational research, targeted therapy, chemoresistance, immunotherapy, and personalized medicine. Numerous Gyn Onc fellows, postdoctoral fellows, graduate students, residents, and medical students have trained under her direct mentorship. She is a member of multiple professional societies and committees both regionally and nationally. She has been awarded funding for over five Investigator Initiated trials and has served as both the local and national Principal Investigator on multiple Phase II and III clinical trials. She is the co-chair of UAB’s Gyn and Personalized Medicine Disease Oriented Working Groups, the Chair of the CCC Data Safety Monitoring Committee, and the Chair of UAB Tissue Committee. She is also the Co-Translational Science Chair of NRG’s Ovarian Committee.

Junzo Chino, MD
Associate Professor, Director of Brachytherapy
Department of Radiation Oncology, Duke Cancer Center

Dr. Chino is an Associate Professor of Radiation Oncology and Director of Brachytherapy at the Duke Cancer Center. He has authored over 100 publications in the peer reviewed literature, and his research interests are concentrated in radiation therapy for gynecologic cancer, as well as health services and disparities. He was lead author of the ASTRO guidelines task force for cervical cancer, and currently serves as the GYN section editor at the International Journal of Radiation Oncology Biology and Physics.
Danielle Enserro, PhD
Biostatistician, Clinical Trial Development Division (CTDD)
at Roswell Park Comprehensive Cancer Center
Statistics and Data Management Center (SDMC), NRG Oncology

Dr. Enserro serves as a Biostatistician for the Clinical Trial Development Division (CTDD) in the Department of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center, which is part of the Statistics and Data Management Center (SDMC) for NRG Oncology, a network group studying adult malignancies in the National Cancer Institute (NCI) National Clinical Trial Network (NCTN). The CTDD is also part of the NRG Oncology NCORP Statistics and Data Management Center (SDMC). Dr. Enserro provides support for the design, monitoring, management, and analysis of phase I-IV clinical trials run by NRG Oncology, Gynecologic Oncology group (GOG) Foundation and Roswell Park Comprehensive Cancer Center. Her primary focus is primarily on gynecologic cancers, as well as cancer control and prevention trials through NRG NCORP.

Britt K. Erickson, MD
Assistant Professor
Division of Gynecologic Oncology
University of Minnesota

Dr. Erickson is a gynecologic oncologist and assistant professor at the University of Minnesota. Her research focuses on chemoprevention and treatment of endometrial cancer and other other gynecologic malignancies. She develops and leads clinical trials at the University of Minnesota and Nationally and has recently been awarded the GOG-Foundation Scholar award for her work in late phase endometrial cancer trial development.

Amanda Nickles Fader, MD
Professor of Gynecology and Obstetrics
Professor of Oncology
Vice-Chair, Gynecologic Surgical Operations
Johns Hopkins School of Medicine

Dr. Fader is a Professor of Gynecologic and Obstetrics and Oncology at the Johns Hopkins School of Medicine. She also serves as Vice Chair of Gynecological Surgical Operations and Director of the Center for Rare Gynecologic Cancers. She is passionate about rare tumor research and clinical trials and has published more than 200 peer-reviewed manuscripts.
Dr. Lilian T. Gien, MD, MSc, FRSC
Professor, Division of Gynecologic Oncology
University of Toronto
Sunnybrook Health Sciences Centre

Dr. Gien is a gynecologic oncologist at the Odette Cancer Center, Sunnybrook Health Sciences Center, in Toronto, Canada, and Professor in the Department of Obstetrics & Gynecology at the University of Toronto. Dr. Gien obtained her Bachelor of Science at Yale University, her degree in Medicine at the University of Western Ontario, residency in Obstetrics & Gynecology at the University of Western Ontario, and her Fellowship in Gynecologic Oncology at the University of Toronto. During her Fellowship, she completed a Master’s of Science in Clinical Epidemiology. Dr. Gien is currently the Gynecologic Cancer Site Group Chair at the Odette Cancer Center.

Dr. Gien is also a Senior Adjunct Scientist in the Cancer Program at the Institute for Clinical Evaluative Sciences (ICES) and an Affiliate Scientist at the Sunnybrook Research Institute. Her research interests are in health services research to determine the effects of care delivery on health outcomes in gynecologic malignancies and in clinical trials for rare gynecologic malignancies, particularly in vulvar cancer. She has been the Principal Investigator for several trials funded by the National Cancer Institute. Dr. Gien was awarded the Gynecologic Oncology Group (GOG) Scholar Investigator Award in 2019. She was also recently awarded over $1 million by the Department of Defense for ovarian cancer research evaluating mechanisms of resistance in PARP-inhibitors in organoid models. In Canada, she is the Past-Chair of the Gynecologic Oncology Subspecialty Committee at the Royal College of Physicians and Surgeons of Canada, and Co-chair of the GOG Partners/Canadian collaboration.

Dr. Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, GMO Westchester
Memorial Sloan Kettering Cancer Center

Dr. Grisham is an Associate Attending within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC) and Associate Professor of Medicine at Weill Cornell Medical College. She is the Section Head of Ovarian Cancer Treatment and the Director of Gynecologic Medical Oncology at MSKCC Westchester. She is board certified in Medical Oncology and received her Medical Degree at Duke University School of Medicine. Dr. Grisham performed her Internal Medicine Internship and Residency at Massachusetts General Hospital. She then came to Memorial Sloan Kettering Cancer Center where she served as the Chief Fellow of the Hematology and Oncology Fellowship Program. Dr. Grisham subsequently joined the Gynecologic Medical Oncology Service in 2012. Dr. Grisham’s research focuses on determining the molecular drivers of low-grade serous ovarian cancer and the development of targeted treatment strategies for patients with recurrent ovarian cancer. She has served as the principal investigator for over 25 clinical trials and serves on multiple committees within ASCO, NRG and SGO. She is a graduate of the ASCO leadership development program, and serves on the GOG Partners Investigators Council, NRG Rare Tumor Committee, NCCN Ovarian Cancer Guidelines Committee, and the ASCO Annual Meeting Scientific Program Committee. Dr. Grisham is the recipient of an ASCO Merit Award, a Conquer Cancer Career Development Award, an Ovarian Cancer Research Fund Liz Tilberis Award, Kaleidoscope of Hope Grants, Cycle for Survival Grants, and a Translational and Integrative Medicine Research Fund Grant.
Tyler Hillman, MD, PHD
Assistant Professor
Dept of Gynecologic Oncology & Reproductive Medicine
Dept of Genomic Medicine
UT MD Anderson Cancer Center

Dr. Hillman’s lab is a joint venture between the Gynecologic Oncology and Reproductive Medicine department and the Genomic Medicine department at The University of Texas MD Anderson Cancer Center. A major focus of the Hillman Lab is pioneering our understanding of the molecular pathogenesis of ovarian granulosa cell tumors. The lab’s work in this area is motivated by Dr. Hillman’s referral practice providing medical and surgical treatment for women affected by this disease. A key long-term goal of his research is to discover new granulosa cell tumor therapeutic vulnerabilities and use these innovations to launch novel early-phase clinical trials focused on this rare disease.

Michael Kelly, MD
Professor, Gynecologic Oncology
Atrium Health Wake Forest Baptist

Elise C. Kohn, MD, FAAAS FASCO
Head, Gynecologic Cancer and Neuroendocrine Cancer Therapeutics
Lead, Core Correlative Science Committee
Cancer Therapy Evaluation Program
Member, Women’s Malignancies Branch
National Cancer Institute
Haider Mahdi, MD, MPH
Gynecologic Oncologist
University of Pittsburgh School of Medicine

Dr. Mahdi is a gynecologic oncologist and physician scientist at University of Pittsburgh School of Medicine/University of Pittsburgh Medical Center. His laboratory is located in Magee Womens Research Institute. His research focus is on modalities to overcome therapy resistance in ovarian and endometrial cancers and to modulate tumor immune microenvironment to enhance response to immunotherapy and agents targeting DNA damage response pathway. In rare tumor, his focus is on high grade neuroendocrine carcinoma (small and large cell) of gynecologic origin.

Alexandra Thomas, MD, FACP
Williams Family Chair in Breast Oncology
Atrium Health Wake Forest Baptist

Dr. Thomas joined the faculty of the Wake Forest Baptist Health Comprehensive Cancer Center in 2016 and currently serve as the leader of the Breast Cancer Disease Oriented Team and Co-Leader of the Breast Cancer Center of Excellence. In 2022 she was named the inaugural Williams Family Chair in Breast Oncology. She completed her undergraduate degree at Princeton and then studied in Rome and worked in Milan before going on to earn her medical degree from Johns Hopkins University School of Medicine. She completed residency at Stanford University Hospital and fellowship at the University of Iowa Hospital. While in Iowa, I served on the faculty at the University of Iowa from 2001 to 2016 and attained the rank of Professor in 2015.

Dr. Thomas’ research focuses on bringing promising laboratory work to the clinic to effectively treat patients with breast cancer. Her areas of interest include cardiotoxicity of breast cancer therapeutics, novel approaches for difficult to treat and rare breast cancers, late recurrence and population-based breast cancer research.

She serves on or has served on multiple national committees including the US National Cancer Institute’s Breast Immuno-Oncology Task Force, the ASCO Annual Meeting Planning Committees and the ASCO Government Relations. She currently serves as Vice Chair of the NRG Protocol Operations Management Committee and as a member of the NRG Core Breast Committee. Dr. Thomas remains highly committed to advocating for public support of improved cancer outcomes and was named the 2018 ASCO Advocate of the Year for her work with elected officials.

Danielle Vicus, MD, MSc, FRCSC
Sunnybrook Health Sciences Centre
Speaker Slide Presentations

A PDF version of all Final Slide Presentations are available in the Symposium Session Content on the Attendee Hub and Meeting App